IL5RA and asthma: Mepolizumab (Nucala) is the first approved monoclonal antibody (mAb) targeting IL-5, blocking the binding of IL-5 to IL-5Rα, which reduces blood eosinophil counts and exacerbations of asthma and improves asthma control [12].